Fast-emerging targets
ADC Target Strategy Radar
Oncology Edition
Map a curated ADC oncology target universe by clinical crowding, clinical maturity, sponsor competition, patent-density signals, and recent momentum.
Built from ClinicalTrials.gov and a conservative patent-signal layer. Outputs are designed to help teams prioritize which ADC targets deserve expert IP and BD attention — not to replace FTO analysis or target-selection advice.
Targets tracked
20
Curated oncology ADC target-modality pairs in the current public screen.
Linked ADC trials
4
ClinicalTrials.gov records linked into the current public target map.
Active or recruiting
4
Active trial count aggregated across the tracked target universe.
Unique sponsors
3
Distinct sponsors mapped into the target screen.
Patent-density signals
7
Signal records from the modular patent layer and local fallback sample.
Manual review required
0
Targets currently flagged for lower-confidence or ambiguous public signals.
Target strategy table
Public target screen
| Target | Strategy | Crowding | Maturity | Patent density | Momentum | Active trials | Sponsors | Confidence |
|---|---|---|---|---|---|---|---|---|
| HER2 / ERBB2 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 1 | 1 | High |
| TROP2 / TACSTD2 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 1 | 1 | High |
| Nectin-4 / NECTIN4 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| B7-H3 / CD276 | Early Watch | Low | Phase 1 Only | Low | Watch | 1 | 1 | High |
| CLDN18.2 / Claudin 18.2 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| FRα / FOLR1 / Folate receptor alpha | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| EGFR | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| c-MET / MET | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| ROR1 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| GPC3 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| PSMA / FOLH1 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| CD30 / TNFRSF8 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| CD33 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| CD79b | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| BCMA / TNFRSF17 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| MUC1 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| NaPi2b / SLC34A2 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| DLL3 | Early Watch | Low | Phase 1 Only | Low | Watch | 1 | 1 | High |
| LIV-1 / SLC39A6 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
| PTK7 | Low Public Signal | Low | Phase 1 Only | Low | Quiet | 0 | 0 | High |
Patent-heavy but clinically light
Signals to review cautiously
Mature late-stage targets
Established programs
Sponsor-target matrix
Sponsor views
- DAIICHI SANKYO: 2 tracked targets
- GILEAD SCIENCES: 1 tracked targets
- ZYMEWORKS: 1 tracked targets
Methodology teaser
Conservative labeling only
Strategy labels are deterministic summaries of public registry and patent-density metadata patterns. They are not conclusions about legal position, clinical superiority, or commercial attractiveness.
ADC access
Receive ADC Target Updates by Email
Use this form to compare two ADC targets, subscribe for email updates, choose CSV interests, track one target monthly, or request a tumor-type-specific cut.